Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Activated partial thromboplastin time | aPTT |
American College of Obstetricians and Gynecologists | ACOG |
Activated protein C | APC |
Adenosine diphosphate | ADP |
Antiphospholipid antibody | APA |
Antiphospholipid syndrome | APS |
Computed tomography | CT |
Computed tomographic pulmonary angiography | CTPA |
Deep venous thrombosis | DVT |
Disseminated intravascular coagulation | DIC |
Enzyme-linked immunosorbent assay | ELISA |
Factor V Leiden | FVL |
Heparin-induced thrombocytopenia | HIT |
Inferior vena cava | IVC |
International normalized ratio | INR |
Low-molecular-weight heparin | LMWH |
Magnetic resonance angiography | MRA |
Magnetic resonance imaging | MRI |
Protein Z–dependent protease inhibitor | ZPI |
Pulmonary embolus | PE |
Systemic lupus erythematosus | SLE |
Thrombin-activatable fibrinolysis inhibitor | TAFI |
Thromboxane A2 | TXA2 |
Tissue factor | TF |
Tissue factor pathway inhibitor | TFPI |
Type 1 plasminogen activator inhibitor | PAI-1 |
Unfractionated heparin | UFH |
Urokinase-type plasminogen activator | uPA |
Venous thromboembolism | VTE |
Venous ultrasonography | VUS |
Ventilation-perfusion scan | V/Q scan |
Pregnancy, childbirth, and the puerperium pose serious challenges to a woman's hemostatic system. While implantation, placentation, and uterine spiral artery remodeling lead to the development of the high-volume, high-flow, low-resistance uteroplacental circulation required for human fetal development, they require enhanced hemostatic responsiveness to avoid potentially fatal hemorrhage. The price paid for this essential hemostatic adaptation to human hemochorial placentation is an increased risk of superficial and deep venous thrombosis (DVT) and pulmonary embolus (PE). Acquired or inherited thrombophilias, obesity, advanced maternal age, advanced parity, antepartum hospitalizations, surgery, and infection are major risk factors for DVT and PE in pregnancy and the puerperium. The expeditious identification and prompt treatment of thrombotic events is critical to avoid death and serious postphlebitic sequelae.
Thrombosis is the obstruction or occlusion of a vessel by a blood clot. Venous thromboembolism (VTE) includes venous thrombosis of the deep venous system of the lower (common) or upper (uncommon) extremity (DVT). Thrombosis or inflammation of the superficial venous system is generally not associated with morbidity, although in some cases it can develop into or be associated with DVT or PE. In fact, 10% to 20% of superficial thrombosis cases in nonpregnant patients are associated with DVT. Pulmonary embolus (PE) is the obstruction of the pulmonary artery or one of its branches, arising from a clot from a DVT in approximately 90% of cases. A majority of PE cases are due to the deportment of thrombus from the lower extremities; for the purposes of this chapter, pulmonary embolus will refer to VTE of the pulmonary vasculature (rather than air, fat, or amniotic fluid embolism).
Occurring in approximately 1 in 1500 pregnancies, VTE is a relatively uncommon disorder but is a leading cause of mortality and serious morbidity in pregnant women. This rate represents a nearly 10-fold increase compared with nonpregnant women of comparable childbearing age . According to the most recent U.S. vital statistics, from 2006 through 2010, VTE was a leading cause of maternal mortality that contributed to 9% of pregnancy-related deaths. Classic teaching viewed the postpartum period as the period of maximal thrombotic occurrence. However, management styles of prior eras that included prolonged puerperal bed rest and estrogen to suppress lactation likely inflated this risk. More recent studies have shown that a majority of thromboembolic events occur in the antepartum period. Given its shorter duration, and after adjusting for duration of exposure, the day-to-day relative risk of VTE is about threefold to eightfold higher in the puerperium. New evidence suggests that the risk for a thrombotic event extends out to 12 weeks postpartum, although the absolute increase in risk is quite low after 6 weeks.
It is well known that inherited mutations in various components of the coagulation cascade, the so-called inherited thrombophilias, contribute to significant risk for thrombosis, especially in the presence of other risk factors such as pregnancy, surgery (e.g., cesarean delivery), trauma, infection, or immobility. Factor V Leiden is the most common mutation and accounts for over 40% of inherited thrombophilias in most studies. Most of these genetic mutations act in an autosomal-dominant manner; thus, one mutation will incur an elevated risk for VTE and individuals with two mutations will have even higher risks for thrombotic events than those with one. Patients with a strong family history of thrombotic events who have screened negative for the panel of known thrombophilia mutations likely have an as-yet unrecognized gene defect in a specific component of the coagulation cascade. The details of the known inherited thrombophilias are discussed later in this chapter.
Vasoconstriction and platelet activity play a primary initial role in limiting blood loss following vascular disruption and endothelial damage. Vasoconstriction limits blood flow and also limits the size of thrombus necessary to repair the defect. Platelet adherence to damaged vessels is mediated by the formation of von Willebrand factor (vWF) “bridges” anchored at one end to subendothelial collagen and at the other to the platelet glycoprotein Ib (GP Ib)/factor IX/V receptor. Platelet adhesion stimulates release of α-granules that contain vWF, thrombospondin, platelet factor 4, fibrinogen, β-thromboglobulin, and platelet-derived growth factor as well as dense granules that contain adenosine diphosphate (ADP) and serotonin. These latter molecules, when combined with the release of thromboxane A 2 (TXA 2 ), contribute to further vasoconstriction and platelet activation. In addition, ADP causes a conformational change in the platelet GP IIb/IIIa receptor that promotes aggregation by forming interplatelet fibrinogen, fibronectin, and vitronectin bridges.
Platelet action alone is insufficient to provide adequate hemostasis in the face of a substantial vascular insult; in this setting, the coagulation cascade—with resultant fibrin plug formation—is required to restore hemostasis . Tissue factor (TF), a cell membrane-bound glycoprotein, is the primary initiator of the coagulation cascade. It is expressed constitutively by epithelial, stromal, and perivascular cells throughout the body and in abundance by endometrial stromal cells and the pregnant uterine decidua. TF is also present in low concentrations in the blood, on activated platelets, and in high levels in amniotic fluid, which accounts for the coagulopathy seen in amniotic fluid embolism. It is interesting to note that although intrauterine survival is possible in the absence of platelets or fibrinogen, it is not possible in the absence of TF. Clotting is initiated by the binding of TF to factor VII, the only clotting factor with intrinsic coagulation activity in its zymogenic form ( Fig. 50.1 ).
Following endothelial injury and in the presence of ionized calcium, perivascular cell- or platelet-bound TF comes into contact with factor VII on anionic cell membrane phospholipids. Factor VII has low intrinsic clotting activity but can be autoactivated after binding to TF, or it can be activated by thrombin or activated factors such as IXa, Xa, or XIIa. The TF–activated factor VII (VIIa) complex initiates the elements of the coagulation cascade by activating both factors IX and X. Activated factor IX (IXa) complexes with its cofactor VIIIa to indirectly activate X. Once generated, Xa binds with its cofactor Va to convert prothrombin (factor II) to thrombin (factor IIa). Cofactors V and VIII can be activated by either thrombin or Xa, and XIIa activates XI on the surface of activated platelets, which provides an alternative route to IX activation. Factor XII can be activated by kallikrein/kininogen as well as by plasmin. The key event of hemostasis occurs when thrombin cleaves fibrinogen to produce fibrin. Fibrin monomers self-polymerize and are cross-linked by thrombin-activated factor XIIIa. Although TF is the initiator of hemostasis, thrombin is the ultimate arbiter of clotting; it not only activates platelets and generates fibrin, it also activates critical clotting factors and cofactors (V, VII, VIII, XI, and XIII). Fig. 50.1 provides a diagram of the interaction of the various components of the coagulation cascade.
The risk of thrombosis, the inappropriate and excessive activation of the clotting cascade, is restrained by the anticoagulant system (see Fig. 50.1 ). Evidence shows that the coagulation system “idles” like a car engine to quickly respond to vascular injury, and thus the anticoagulant system performs the critical role of preventing the inappropriate acceleration of clotting. Tissue factor pathway inhibitor (TFPI) binds to the prothrombinase complex (factor Xa/TF/factor VIIa) to stop TF-mediated clotting. However, as noted, factor XIa generation can bypass this block. Moreover, in the 10 to 15 seconds before TFPI-mediated prothrombinase inhibition, sufficient quantities of factors Va, VIIIa, IXa, and Xa and thrombin are generated to sustain clotting for some time. As a result, additional physiologic anticoagulant molecules are required to maintain blood fluidity.
Paradoxically, thrombin also plays a pivotal role in the anticoagulant system by binding to thrombomodulin, which causes a conformation change that allows it to activate protein C. The activated protein C (APC) molecule binds to anionic endothelial cell membrane phospholipids on damaged vessels or to the endothelial cell protein-C receptor (EPCR) to inactivate factors Va and VIIIa. Protein S is an important cofactor in this process because it enhances APC activity. Factor Va is also a cofactor in APC-mediated factor VIIIa inactivation.
Factor Xa can also be inhibited by the protein Z–dependent protease inhibitor (ZPI). When ZPI forms a complex with its cofactor, protein Z, its inhibitory activity is enhanced a thousand-fold, although ZPI can also inhibit factor XIa independent of protein Z. Deficiencies of protein Z can promote both bleeding and thrombosis, although the latter predominates particularly in the presence of other thrombophilias.
Thrombin activity is modulated by a number of serine protease inhibitors—such as heparin cofactor II, α-2 macroglobulin, and antithrombin—which serve to inactivate thrombin and Xa . The most active inhibitor within this group is antithrombin, which binds to either thrombin or factor Xa and then to heparin or other glycosaminoglycans, augmenting antithrombin's rate of thrombin inactivation more than a thousand-fold. The other two inhibitors work in a similar fashion to inhibit thrombin.
Fibrinolysis is a further critical element in preventing overwhelming thrombosis (see Fig. 50.1 ). Tissue-type plasminogen activator (tPA), an endothelial enzyme metabolized by the liver, becomes embedded in fibrin and cleaves plasminogen to generate plasmin, which in turn cleaves fibrin into fibrin degradation products; the latter are indirect measures of fibrinolysis. These fibrin degradation products can also inhibit thrombin action, a favorable effect when production is limited but a contributor to disseminated intravascular coagulation (DIC) when production is excessive. A second plasminogen activator, urokinase-type plasminogen activator (uPA), is produced by endothelial cells. A series of fibrinolysis inhibitors also prevent hemorrhage from premature clot lysis. The α-2 plasmin inhibitor is bound to the fibrin clot, where it prevents premature fibrinolysis. Platelets and endothelial cells release type 1 plasminogen activator inhibitor (PAI-1), an inactivator of tPA. In pregnancy, the decidua is also a rich source of PAI-1, whereas the placenta produces mostly type 2 (PAI-2). The thrombin-activatable fibrinolysis inhibitor (TAFI) is another fibrinolytic inhibitor that is also activated by the thrombin-thrombomodulin complex. TAFI modifies fibrin and renders it resistant to inactivation by plasmin.
Characteristic physiologic changes in decidual and systemic hemostatic systems occur in pregnancy in preparation for the hemostatic challenges of implantation, placentation, and childbirth. Decidual TF and PAI-1 expression are greatly increased in response to progesterone, and levels of placental-derived PAI-2, which are negligible prior to pregnancy, increase until term. Pregnancy is associated with systemic changes that enhance hemostatic capability and promote thrombosis. For example, a doubling occurs in circulating concentrations of fibrinogen, and 20% to 1000% increases are seen in factors VII, VIII, IX, X, and XII, all of which peak at term in preparation for delivery. Levels of vWF also increase up to 400% at term. In contrast, levels of prothrombin and factor V remain unchanged, and levels of factor XIII and XI decline modestly. Concomitantly, there is a 40% to 60% decrease in the levels of free protein S, conferring an overall resistance to activated protein C. Further reductions in free protein-S concentrations are caused by stress, cesarean delivery, and infection; this accounts for the high rate of PE following cesarean deliveries, particularly in association with prolonged labor and endomyometritis. Coagulation parameters may normalize as early as 3 weeks postpartum, but they generally return to baseline at 6 to 12 weeks.
The risk of thrombosis in pregnancy is also related to physical changes in the gravid woman. Venous stasis in the lower extremities results from compression of the inferior vena cava (IVC) and pelvic veins by the enlarging uterus . Despite the presence of the sigmoid colon promoting uterine dextrorotation, ultrasound findings indicate lower flow velocities in the left leg veins throughout pregnancy. This would explain why multiple studies have confirmed that the incidence of thrombosis is far greater in the left leg than in the right . Hormone-mediated increases in deep vein capacitance secondary to increased circulating levels of estrogen and local production of prostacyclin and nitric oxide also contribute to the increased risk of thrombosis.
Overall, antiphospholipid syndrome (APS) is responsible for approximately 14% of thromboembolic events in pregnancy . The diagnosis of APS requires the presence of prior or current vascular thrombosis or characteristic obstetric complications together with at least one of the following laboratory criteria: anticardiolipin antibodies (immunoglobulin G [IgG] or IgM greater than 40 GPL [1 GPL unit is 1 µg of IgG antibody] or 40 MPL [1 MPL unit is 1 µg of IgM antibody] or greater than the 99th percentile), anti–β-2 glycoprotein-I (IgG or IgM greater than the 99th percentile), or lupus anticoagulant.
The antiphospholipid antibodies (APAs) are a class of self-recognition immunoglobulins whose epitopes are proteins bound to negatively charged phospholipids. These antibodies must be present on two or more occasions at least 12 weeks apart for diagnosis and are present in 2.2% of the general obstetric population. Most affected patients have uncomplicated pregnancies. Thus providers should use caution when ordering and interpreting tests in the absence of APS-qualifying clinical criteria.
APS has been associated with both venous (DVT, PE) and arterial vascular events (stroke). A meta-analysis of 18 studies has shown elevated risk of DVT, PE, and recurrent VTE among patients with systemic lupus erythematous (SLE) who test positive for antiphospholipid antibodies. Overall, when compared to those SLE patients who do not test positive for either test, those with lupus anticoagulants and anticardiolipin antibodies have a respective sixfold and twofold increased risk of venous thrombosis. These antibodies also pose a risk to patients without SLE. The lifetime prevalence of arterial or venous thrombosis in affected non-SLE patients is approximately 30%, with an event rate of 1% per year . The risks of thromboembolic events are highly dependent on the presence of other predisposing factors that include pregnancy, estrogen exposure, immobility, surgery, and infection. As noted above, APS has also been associated with adverse pregnancy outcome and accounts for 14% of VTE in pregnancy. In fact, the risk of a thrombotic event in pregnancy is 5% even with prophylaxis. All patients who present with VTE in pregnancy or in the postpartum period should have an appropriate APS workup.
The inherited thrombophilias are a heterogeneous group of genetic disorders associated with arterial and venous thrombosis as well as fetal loss. As with APAs, the occurrence of a thromboembolic event is highly dependent on other predisposing factors such as pregnancy, exogenous estrogens, immobility, obesity, surgery, infection, trauma, and the presence of other thrombophilias. However, the most important risk modifier is a personal or family history of venous thrombosis. Table 50.1 presents the prevalence and risk of venous thrombosis among pregnant patients with and without a personal or family history of venous thrombosis. As noted, the thrombophilias are divided into high and low risk based on the overall risk of VTE. The screening for and management of inherited thrombophilias during and around the time of pregnancy has been addressed by American College of Obstetricians and Gynecologists (ACOG). All patients who present with VTE in pregnancy or postpartum should be considered for an appropriate workup for inherited thrombophilias.
Risk | Thrombophilia Type | Prevalence in the European Population | Prevalence in Patients With VTE in Pregnancy | RR/OR of VTE IN Pregnancy (95% CI) | Probability of VTE in Pregnant Patients With Personal or Family HX | Probability of VTE in Pregnant Patients Without Personal or Family HX | Study |
---|---|---|---|---|---|---|---|
High risk | FVL homozygous | 0.07% a | <1% a | 25.4 (8.8–66) | ≫10% | 1.5% | 41, 136–139 |
Prothrombin gene G20210A mutation homozygous | 0.02% a | <1% a | N/A | ≫10% | 2.8% | 140, 141 | |
Antithrombin III deficiency | 0.02%–1.1% | 1%–8% | 119 | 11%–40% | 3.0%–7.2% | 136, 139, 140 | |
Compound heterozygous (FVL/prothrombin G20210A) | 0.17%+ | <1%+ | 84 (19–369) | 4.7% (overall probability of VTE in pregnancy) | 41, 136, 142 | ||
Low risk | FVL heterozygous | 5.3% | 44% | 6.9 (3.3–15.2) | >10% | 0.26% | 41, 136–138, 143 |
Prothrombin G20210A mutation heterozygous | 2.9% | 17% | 9.5 (2.1–66.7) | >10% | 0.37%–0.5% | 41, 136, 141, 142 | |
Protein C deficiency | 0.2%–0.3% | <14% | 13.0 (1.4–123) | NA | 0.8%–1.7% | 136, 139, 140, 144 | |
Protein S deficiency | 0.03%–0.13% | 12.4% | NA | NA | <1%–6.6% | 41, 136, 140, 145 |
Recent prospective studies have suggested that lower-risk inherited thrombophilias may have an even weaker association with maternal thrombosis than that reported by the retrospective studies cited in Table 50.1 . For example, a prospective study of 4885 low-risk women screened in the first trimester of pregnancy noted that 134 (2.7%) carried the factor V Leiden mutation, but none had a thromboembolic event during pregnancy or the in puerperium (95% confidence interval [CI], 0% to 2.7%). In two other prospective studies that involved 584 pregnant Irish and 4250 British women, again screened for factor V Leiden early in pregnancy, no thrombotic episodes were noted among carriers. Said and associates blindly tested 1707 Australian nulliparous women for factor V Leiden, the prothrombin gene G20210A mutation, and a thrombomodulin polymorphism prior to 22 weeks, and reported an expected prevalence of heterozygosity for the factor V Leiden and prothrombin G20210A gene mutations and homozygosity for the thrombomodulin polymorphism of 5.39%, 2.38%, and 3.51%, respectively; again, none of the patients developed VTEs. However, one prospective study of 2480 women tested for activated protein-C resistance/factor V Leiden early in pregnancy and observed that affected patients had an eightfold increase in VTE. Thus, the true risk of thrombosis in patients with low-risk inherited thrombophilias is probably lower than that suggested by retrospective case-control and cohort studies and is likely also dependent on the presence of concomitant risk factors such as a strong family history, obesity, and surgery.
Virchow triad—vascular stasis, hypercoagulability, and vascular trauma—describes the three classic antecedents to thrombosis, and many of the physiologic changes of pregnancy contribute to these criteria . Other pregnancy-specific risk factors for thrombosis include increased parity, multiple gestation, preeclampsia, postpartum endomyometritis, postpartum hemorrhage requiring transfusion, operative vaginal delivery, and cesarean delivery. The latter is associated with a fourfold increase in VTE risk compared with vaginal delivery, with emergent cesarean delivery increasing the risk of VTE even further. Risk factors not unique to pregnancy include age greater than 35 years, obesity (body mass index ≥30 kg/m 2 ), trauma, paralysis, smoking, nephrotic syndrome, hyperviscosity syndromes, cancer, surgery (particularly orthopedic procedures), and a history of DVT or PE ( Table 50.2 ). There are also reversible risk factors that can increase the risk of VTE in pregnancy including ovarian hyperstimulation syndrome, infection, immobility, long-distance travel (>4 to 6 hours), hyperemesis with associated dehydration and hospital stay/bedrest. Admission to the hospital in pregnancy may be associated with a 17-fold increased risk for VTE compared with a nonhospitalized cohort, with this risk remaining high (sixfold) for the 28 days after admission . In vitro fertilization (IVF) has been shown to increase the risk for VTE in the first trimester in a cross-sectional study in Sweden, although the overall absolute risk is still rather low.
General | Pregnancy Related | Transient |
---|---|---|
Age >35 years | Increased parity | Immobility/hospital admission |
Obesity | Postpartum endomyometritis | Infection |
Trauma | Operative vaginal delivery | Hyperemesis |
Paralysis | Cesarean delivery | Long distance travel, >4 to 6 h |
Multiple gestation | Ovarian hyperstimulation syndrome | |
Smoking | Postpartum hemorrhage requiring transfusion | |
Nephrotic syndrome | Preeclampsia | |
Hyperviscosity syndromes | ||
Cancer | ||
Surgery, especially orthopedic | ||
Prior deep venous thromboembolism or pulmonary embolism |
Thromboembolism is associated with serious complications that include arrhythmia, hypoxia, pulmonary hypertension, heart failure, and postthrombotic syndrome of the extremities. Thromboembolism is a major cause of death worldwide; thus prompt diagnosis and treatment is a priority. When confronted with the signs and symptoms suggestive of VTE, rapid initiation of the workup and treatment is essential to avoid complications. Complications of anticoagulation, such as bleeding or thrombocytopenia, are also a reality and should be avoided.
Pregnancy and the postpartum period are considered high-risk periods for thromboembolism. Key considerations in the workup and management of pregnant women include the selection of appropriate diagnostic tools and anticoagulation regimens with special concern regarding pregnancy-related changes and fetal exposures.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here